Latest Safety News

Page 14 of 252
LTR Pharma has completed the final Phase II pharmacokinetic report for SPONTAN, confirming a median 10-minute time to peak concentration against 60 minutes for an oral vardenafil tablet. The result completes the FDA-aligned dataset ahead of planned US submission work, although efficacy in erectile dysfunction patients remains to be tested.
Victor Sage
Victor Sage
1 Oct 2026
ClearVue Technologies reported just A$108,484 of FY2026 revenue against an A$11.86 million loss, while consuming A$8.69 million in operating cash. The solar-glazing developer says certifications, international partners and an 80-project pipeline have strengthened its platform, but the next test is converting those assets into cash revenue.
Victor Sage
Victor Sage
30 Sept 2026
KGL Resources says its Jervois copper project is funded through construction and ramp-up after a US$300 million Wheaton agreement and a post-year-end A$300 million equity raising. The company is now targeting a final investment decision in the second half of 2026 and first copper concentrate in 2028, while its annual report highlights the execution risks still attached to that timetable.
Maxwell Dee
Maxwell Dee
30 Sept 2026
Imagion Biosystems has secured central ethics approval for its US Phase 1b/2 trial of the MagSense HER2 imaging agent, removing a key requirement before recruitment can begin. Site activation is now underway, but no patient has yet been enrolled and the announcement provides no clinical data.
Ada Torres
Ada Torres
30 Sept 2026
Vectus Biosystems has secured a pre-IND Type B meeting with the FDA for its lead IPF drug candidate VB0004. The regulator’s written feedback, expected by mid-November, should clarify the next US development steps but does not yet authorise clinical trials.
Ada Torres
Ada Torres
30 Sept 2026
Jupiter Mines delivered above-target production and sales at its Tshipi manganese mine in FY26, but higher costs and a stronger South African rand pulled group profit lower. The year also brought a new majority co-investor, a leadership transition and fresh questions around the mine’s resource and reserve base.
Maxwell Dee
Maxwell Dee
30 Sept 2026
EQ Resources has completed a sharp financial turnaround, moving from solvency concerns to a A$7.1 million FY2026 profit and A$28.2 million of cash. The recovery comes with lower annual production, serious safety shortcomings and substantial dilution, leaving execution as the test for its A$39 million Mt Carbine expansion.
Maxwell Dee
Maxwell Dee
30 Sept 2026
Metallium has moved Flash Joule Heating from tiny laboratory tests to multi-reactor campaigns in Texas, backed by feedstock contracts, offtake and A$125 million raised during FY2026. Yet the ASX-listed group remains pre-revenue, lost A$42.8 million and says continued access to funding is a material uncertainty.
Victor Sage
Victor Sage
30 Sept 2026
Cauldron Energy has expanded its defined Yanrey uranium resource to 55.6 million pounds of U3O8 after a successful exploration year, while warning that further funding will be needed to continue operations. The project remains dependent on a change to Western Australia’s uranium mining policy.
Maxwell Dee
Maxwell Dee
29 Sept 2026
TrivarX has made Stabl-Im its central development bet, but the ASX-listed health technology company also reported an $8.76 million FY2026 loss and an auditor-flagged material uncertainty over its ability to continue without further funding. The planned Phase 1 study remains subject to regulatory, ethics and operational clearances.
Ada Torres
Ada Torres
29 Sept 2026
Patrys has moved its injectable quetiapine program into human testing, while its FY2026 annual report warns the company will need further funding within 12 months. The company ended the year with $3.36 million in cash after raising capital and acquiring the RLS-2202 development program.
Victor Sage
Victor Sage
28 Sept 2026
Cynata Therapeutics (ASX:CYP) has reported a $9.25 million loss, negative net assets and a material uncertainty over going concern after its two major clinical trials failed to demonstrate efficacy. The company has since cut its workforce to zero, shifted management to the board and secured a $600,000 R&D tax incentive loan while it considers the future of its Cymerus platform.
Ada Torres
Ada Torres
28 Sept 2026

Browse the archive

Full archive